Applied Clinical Trials Direct
Having trouble viewing this e-mail? Click here.
  June 4, 2013
In This Edition
News Roundup: Drug Safety in Demand
Blog Posts: Woodcock Maps Path for Personalized Medicine
Marketplace: Marketplace

Stop by CenterWatch’s booth #728 at DIA in Boston—enter to win a Kindle!
Visit our booth to learn more about our new eBooks, the 2013 Clinical Trials Data Library and which sponsors and CROs ranked highest among sites in our latest relationship survey! Plus, pick up a copy of the June CenterWatch Monthly, find out about attendee-only discounts and register to win an Amazon Kindle Fire! See you in our hometown of Boston!.  Read More

News Roundup
bullet Europe’s New Clinical Trials Rules Inch Forward
bullet Drug Safety Enhanced with Temp Roles
bullet GSK Complements RBM Plan with CluePoints
bullet EMA Releases Data on Staff, Inspections
bullet Vote on Your Favorite Topic Today


Blogs Posts
bullet Woodcock Maps Path for Personalized Medicine
bullet Sponsors Leery of Joint Inspections


Sponsored
Improving Clinical Operations with Digital Signatures
On Demand Webcast
Register Free at: www.appliedclinicaltrialsonline.com/digitalsignatures

Sponsored
IRT & EDC – Are You Ready for the Unified Experience?
On Demand Webcast
Register Free at: www.appliedclinicaltrialsonline.com/experience

Events
bullet CBI’s 5th Forum on Clinical Trial Budgeting and Project Management
bullet Clinical Patient Engagement Summit

Sponsored
How Innovative Outsourcers Are Succeeding at Virtual Trial Management
On Demand Webcast
Register Free at: www.appliedclinicaltrialsonline.com/innovative

Marketplace

Sponsored
A lot of CROs offer databases. But only Covance offers Xcellerate®, a more strategic approach to Clinical Trial Optimization ® Learn More

Sponsored
Drug Development Strategies in China
Pharma and biotech firms who are relative newcomers to the Chinese market aren't aware that the regulatory climate has changed dramatically in recent years. SFDA approval times for Clinical Trials Approvals have dropped to 7-9 months for small molecules. There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a parallel approval strategy. Even without final details (like final dosing) it’s possible to file a CTA for Phase III based on the most current early phase results. This parallel submission strategy can shave several months off the final approval time in China. Learn More



Sponsored
New Strategies to Expedite Go/No Go Decisions in Oncology Trials
Live Webcast: Thursday, 13 June 2013 at 11:00 am EDT
Register Free at: www.appliedclinicaltrialsonline.com/oncologytrials


Follow Us

Ask The Editor

Lisa Henderson
Editor in Chief
[email protected]